Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
暂无分享,去创建一个
[1] J. Bruix,et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Gravitz. Liver cancer , 2014, Nature.
[3] J. Llovet,et al. Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning , 2014, Nature Reviews Clinical Oncology.
[4] M. Kudo,et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Kudo,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Wen-Tsung Huang,et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). , 2013 .
[7] Pei-Jer Chen,et al. Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma , 2013, Cancer.
[8] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[9] A. Zhu,et al. Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC) , 2012 .
[10] A. Gasbarrini,et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). , 2012 .
[11] S. Imbeaud,et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.
[12] V. Mazzaferro,et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. , 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[14] J. Llovet,et al. Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib , 2012, Clinical Cancer Research.
[15] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[16] R. Finn,et al. Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.
[17] R. Perez-soler,et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. , 2011, The New England journal of medicine.
[18] M. Thomas,et al. Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.
[19] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[20] Derek Y. Chiang,et al. Cancer gene discovery in hepatocellular carcinoma. , 2010, Journal of hepatology.
[21] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[22] Derek Y. Chiang,et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.
[23] E. Raymond,et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. , 2009, The Lancet Oncology.
[24] Marek Ancukiewicz,et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[26] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[27] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[28] Derek Y. Chiang,et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.
[29] B. Daniele,et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .
[30] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Jin Woo Kim,et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.
[32] Jeffrey S. Morris,et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.
[33] Derek Y. Chiang,et al. Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.
[34] S. Boyault,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.
[35] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[36] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[38] P. Philip,et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Thorgeirsson,et al. Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.
[40] M. Salgaller. American Association for Cancer Research , 2000, Expert opinion on investigational drugs.
[41] J. Bruix,et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.
[42] F. Izzo,et al. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.
[43] A. Hettinger,et al. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. , 1998, Journal of hepatology.
[44] P F Thall,et al. New designs for the selection of treatments to be tested in randomized clinical trials. , 1994, Statistics in medicine.
[45] G. Práctica,et al. European Association for the Study of the Liver , 1971 .
[46] J. Llovet,et al. Medical therapies for hepatocellular carcinoma: a critical view of the evidence , 2013, Nature Reviews Gastroenterology &Hepatology.
[47] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[48] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[49] A. Jemal,et al. Global Cancer Statistics , 2011 .
[50] E. Raymond,et al. [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.
[51] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[52] S. Elledge,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[53] Riccardo Lencioni,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.
[54] Ronald A. DePinho,et al. Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.
[55] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[56] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[57] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.